TL;DR: The Centers for Medicare & Medicaid Services modified NCD 130, the National Coverage Determination governing Medicare coverage of tumor antigen CA 125 by immunoassay, effective March 7, 2026. Here's what billing teams need to know.
This update to the CMS CA 125 coverage policy refines when Medicare covers serum CA 125 testing — and when it doesn't. The policy does not list specific CPT or HCPCS codes directly within NCD 130 itself, but CMS points to quarterly Covered Code Lists for applicable billing codes. If your practice bills CA 125 testing for oncology or gynecology patients on Medicare, audit your documentation against these criteria before submitting claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Tumor Antigen by Immunoassay — CA 125 |
| Policy Code | NCD 130 (NCD 130-v2) |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium — narrow but strict coverage rules with meaningful claim denial risk |
| Specialties Affected | Gynecologic Oncology, Medical Oncology, Laboratory/Pathology, Obstetrics & Gynecology |
| Key Action | Audit CA 125 orders against covered indications and confirm documentation supports medical necessity before billing |
CMS CA 125 Coverage Criteria and Medical Necessity Requirements 2026
The CMS CA 125 coverage policy covers serum CA 125 testing under Medicare in specific, defined clinical situations. Outside those situations, claims will deny. Full stop.
CA 125 is a high molecular weight serum tumor marker. It's elevated in about 80% of patients presenting with epithelial ovarian carcinoma, as well as in carcinomas of the fallopian tube, endometrium, and endocervix. Medicare also recognizes elevation in malignant mesothelioma and primary peritoneal carcinoma as covered contexts.
The policy spells out four distinct covered uses, each with its own documentation requirements. Your billing team needs to know all four.
Pre-operative baseline. A CA 125 level is covered as part of the initial pre-operative work-up for women with a suspicious pelvic mass. The key word here is "baseline" — the documentation must show the test is tied to pre-operative evaluation and future post-operative monitoring, not just general diagnostic workup.
Post-treatment CA 125 half-life calculation. Three serum CA 125 levels during the first month after initial surgery or chemotherapy for ovarian carcinoma are covered to calculate the patient's CA 125 half-life. This has prognostic implications CMS explicitly recognizes. Document the clinical rationale for each draw and tie it to the post-treatment monitoring protocol.
Assessment of residual disease after chemotherapy. CA 125 levels at the completion of chemotherapy are covered as an index of residual disease. Again, your documentation needs to reflect that this is an end-of-treatment assessment, not an interim check.
Surveillance and response monitoring. CMS covers surveillance CA 125 measurements at defined intervals: every three months for two years, every six months for the next three years, and yearly after that. For patients with advanced or recurrent disease, CA 125 levels are also covered before each treatment cycle as an indicator of treatment response.
The medical necessity case for CA 125 billing rests entirely on tying each test to one of these covered indications. If your documentation doesn't connect the order to a specific covered use, you're looking at a claim denial.
Prior authorization is not mentioned in NCD 130 as a requirement for CA 125 testing under Medicare. However, this policy does cross-reference the Medicare Claims Processing Manual, Chapter 120, for clinical laboratory services billing guidelines — so your billing team should confirm applicable claims processing rules are reflected in your workflow.
CMS CA 125 Exclusions and Non-Covered Indications
This is where billing teams get into trouble. The policy is explicit about two non-covered uses, and both are common clinical scenarios.
Signs and symptoms suggestive of malignancy — not covered. CMS will not reimburse CA 125 testing when a provider orders it to evaluate a patient who presents with signs or symptoms that suggest malignancy. This is counterintuitive to some clinicians, but the policy is clear. The test is for monitoring, not for initial diagnostic evaluation in symptomatic patients.
Differential diagnosis of a pelvic mass — not covered. This is probably the most important exclusion for gynecology billing teams. CMS specifically excludes CA 125 for aiding in the differential diagnosis of patients with a pelvic mass. The reason: the sensitivity and specificity of the test isn't good enough for this use case. Ordering CA 125 to help sort out whether a pelvic mass is benign or malignant? That claim will not be reimbursed under Medicare.
The real risk here is documentation that's too vague. If a physician's note says something like "pelvic mass, ordering CA 125 to evaluate" without establishing this is a pre-operative baseline in the appropriate context, Medicare will read that as differential diagnosis evaluation and deny the claim.
If your providers are ordering CA 125 in either of these non-covered scenarios, that's a compliance problem — not just a billing problem. Talk to your compliance officer before the effective date of March 7, 2026 if this pattern exists in your practice.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Pre-operative baseline in women with suspicious pelvic mass | Covered | See CMS quarterly Covered Code Lists | Must be documented as baseline for post-operative monitoring |
| Three CA 125 levels in first month post-surgery/chemotherapy (half-life calculation) | Covered | See CMS quarterly Covered Code Lists | Specifically for ovarian carcinoma; three draws within first month post-treatment |
| CA 125 at completion of chemotherapy (residual disease index) | Covered | See CMS quarterly Covered Code Lists | End-of-chemotherapy assessment only |
| Surveillance — every 3 months for 2 years post-treatment | Covered | See CMS quarterly Covered Code Lists | Strict interval schedule; document surveillance protocol |
| Surveillance — every 6 months for years 3–5 post-treatment | Covered | See CMS quarterly Covered Code Lists | Interval change from quarterly; document transition |
| Yearly surveillance after year 5 | Covered | See CMS quarterly Covered Code Lists | Annual draw only |
| Prior to each treatment cycle in advanced/recurrent disease | Covered | See CMS quarterly Covered Code Lists | Must document advanced or recurrent disease status |
| Evaluation of signs or symptoms suggestive of malignancy | Not Covered | N/A | CMS excludes this use explicitly |
| Differential diagnosis of pelvic mass | Not Covered | N/A | Sensitivity and specificity deemed insufficient; claim will deny |
CMS CA 125 Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull your quarterly Covered Code Lists now. NCD 130 does not embed specific CPT or HCPCS codes directly in the policy. CMS maintains quarterly Covered Code Lists — including narrative descriptions — linked from the NCD. Get those lists and confirm your charge capture reflects the current covered codes before March 7, 2026. |
| 2 | Audit your CA 125 orders for the two non-covered indications. Run a report on CA 125 claims from the past 12 months and identify any tied to differential diagnosis of pelvic mass or general evaluation of malignancy symptoms. If you find a pattern, flag it for your compliance officer immediately. This is a reimbursement and compliance issue. |
| 3 | Update your order entry templates and documentation requirements. Providers need to document which covered indication applies to every CA 125 order. Build that prompt into your EHR order entry — a free-text field or a required dropdown isn't optional here. Vague documentation is the fastest path to a claim denial. |
| 4 | Set up surveillance interval tracking. The policy's surveillance schedule is specific: quarterly for two years, every six months for years three through five, then annually. If your practice doesn't have a mechanism to track where each ovarian carcinoma patient sits in that schedule, build one. Billing outside the defined intervals exposes you to denial and potential recoupment. |
| 5 | Confirm your billing guidelines against Chapter 120 of the Medicare Claims Processing Manual. The NCD cross-references this chapter for clinical laboratory services. Your billing team should review Chapter 120 to confirm claims processing rules are applied correctly — particularly for the multi-draw scenarios like the post-treatment half-life calculation. |
| 6 | Brief your ordering providers on the pre-operative baseline vs. differential diagnosis distinction. This is the line most likely to get crossed. A provider ordering CA 125 pre-operatively needs to document "baseline for post-operative monitoring in confirmed planned surgery for suspicious pelvic mass" — not just "suspicious pelvic mass, evaluate." Train your providers on the exact language that supports medical necessity under this policy. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for CA 125 Tumor Antigen Testing Under NCD 130
Covered CPT and HCPCS Codes
NCD 130 does not list specific CPT or HCPCS codes within the policy document itself. CMS maintains quarterly Covered Code Lists — with narrative descriptions — that correspond to this NCD. These lists are updated on a quarterly schedule and are accessible through the NCD 130 policy page on the CMS website.
Your CA 125 billing team should pull the current quarterly Covered Code List directly from CMS and confirm the applicable codes before billing. Do not rely on codes derived from older versions of this policy or third-party sources without verifying against the current quarterly list.
Key ICD-10-CM Diagnosis Codes to Support Medical Necessity
NCD 130 does not specify ICD-10-CM codes in the policy text. However, based on the covered indications described in the policy, your documentation should include diagnosis codes that correspond to:
- Epithelial ovarian carcinoma
- Carcinoma of the fallopian tube
- Carcinoma of the endometrium
- Carcinoma of the endocervix
- Malignant mesothelioma
- Primary peritoneal carcinoma
Work with your coding team to map the appropriate ICD-10-CM codes to each of these diagnoses. The medical necessity determination for CA 125 billing depends on the diagnosis code matching a covered indication — a code that suggests "pelvic mass, unspecified" without an established malignancy will not support a covered claim under this policy.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.